About Products Value to Hospital Patients Resources News Contact Us 5-7F Arterial and Venous Closure SAFE SIMPLE GUARANTEED ORDERING INFO GUARANTEED SHARING RISK BY SHARING COSTS The Vascade Performance Guarantee Because Cardiva Medical® is so committed and confident in VASCADE’s® ability to safely and rapidly achieve hemostasis, we offer a unique value-based purchasing program called the VASCADE® Performance Guarantee™. In the event of a complication as the result of VASCADE, Cardiva Medical will provide significant financial reimbursement to your hospital or practice. It’s simple, we’re dedicated to exceptional outcomes for you and your patients. We stand behind our product based upon published clinical studies and demonstrated superior performance in the surgical theater. Very Low Complication Rates, Rapid Hemostasis in Large Multi-Center Trial In a multi-center, prospective randomized trial, VASCADE demonstrated rapid hemostasis and low complication rates. In this trial, there were no major complications and the incidence of minor complications was significantly reduced as compared to manual compression.1 VASCADE is the only extravascular closure device to offer collagen and a dual method of action, mechanical and physiological. The collagen patch provides a tamponade as a result of rapid expansion of the implant in the presence of fluid. This action ensures the tissue tract is sufficiently filled and provides mechanical hemostasis. The natural thrombogenic property of collagen accelerates coagulation to produce physiological hemostasis. RESPECT TRIAL RESULTS Published in the Journal of Invasive Cardiology Multi-center, prospective, randomized trial of 420 patients across 21 centers (20 in the US and 1 in Australia). Subjects were randomly assigned in a 2:1 ratio VASCADE to MC. 81% of VASCADE cases reported pre-procedure anticoagulant and/or antiplatelet administration. Of note, 8% of VASCADE cases had peri-procedural GP IIb/IIIa inhibitors and 77% of IX VASCADE cases were administered bivalirudin. VASCADE Achieves Rapid Hemostasis, Even in Heparinized Blood In Vitro testing demonstrated VASCADE collagen decreases clotting time in both heparinized and non-heparinized blood when compared against control.5 1RESPECT Trial: Hermiller JB, et.al. A Prospective, Randomized, Pivotal Trial of a Novel Extravascular Collagen-Based Closure Device Compared to Manual Compression in Diagnostic and Interventional Patients Journal of Invasive Cardiology 2015;27(3):129-136. 5Porcine blood was heparinized to 0.42 IU of Heparin/1ml of blood. Data on file. VASCADE® Videos and Literature VASCADE® VCS Deployment Technique A Physician Perspective on VASCADE Vascular Closure System: Dr. Craig Walker A Physician Perspective on the VASCADE Performance Guarantee: Dr. Barry Bertolet A Physician Perspective on VASCADE: Dr. John Lipman Learn More About Dr. Lipman Doctor and Patient Perspectives on UFE: Lisa Rogers and Dr. John Lipman A UFE Patient Journey: Lisa Rogers A Business Leader Perspective on Value in Technology: Roger Owens VASCADE VCS Procedure Dr. Al Khaled Case 1 LIT 5085 Rev A VASCADE VCS Procedure Dr. Al Khaled Case 2 LIT 5086 Rev A VASCADE VCS Procedure Dr. Al Khaled Case 3 LIT 5087 Rev A VASCADE VCS Procedure Dr. Al Khaled Case 4 LIT 5088 Rev A VASCADE VCS Procedure Dr. Al Khaled Case 5 LIT 5089 Rev A VASCADE Product Brochure VASCADE Patient Brochure VASCADE Instructions for Use RESPECT JIC Publication LATEST NEWS JULY 16 Cardiva Medical Announces First... READ MORE JULY 16 Cardiva Medical Announces First... READ MORE JULY 14 Cardiva Medical Announces $45 Million... READ MORE Call us today Toll Free: (in the U.S.) 1-866-602-6099 Need to speak with a Cardiva Representative? REQUEST A CALL Directions 1615 Wyatt Drive Santa Clara, CA 95054 Email Us customerservice@ cardivamedical.com About Us Products Value to Hospital Patients Resources News Contact Us IFUs © 2021 Cardival Medical, Inc. VASCADE®, VASCADE MVP®, and Cardiva CATALYST® are registered trademarks of Cardiva Medical, Inc.. Document Portal Privacy Policy Site Map